Clinical trial readout dates for Ligand Pharmaceuticals Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
| Phase 3 Lasofoxifene + abemaciclib ER+/HER2- breast cancer with an ESR1 mutation | April 2027 Enrollment Initiation |
| Phase 2 AT278-AID System Diabetes | date not published Trial Planned |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 3 ZTALMY (ganaxolone) Refractory status epilepticus (RSE) | March 30, 2024 Ongoing |
Ligand Pharmaceuticals Incorporated reported $447M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-30). Its net loss for that quarter was $28M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |